

Investor update call details

SYDNEY, Australia, 15 July 2019: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, today advises that it will be providing an investor update on Monday, 15 July 2019 at 11:30am AEST.

For those wishing to dial into the call, please see details below:

Investor Teleconference 11:30am AEST Today

15 July 2019

You are invited to participate. Led by MD & CEO Leslie Chong

Conference ID **10001197**

Australia Toll Free: 1800 558 698

Australia Alt. Toll Free: 1800 809 971

USA/Canada Toll Free: 1855 881 1339

UK Toll free: 0800 051 8245

Hong Kong: 800966806

China: 4001200659

New Zealand: 0800453055

Other International: +61731454010

For further information please contact:

Leslie Chong

Managing Director and Chief Executive Officer

T: +61 458 040 433

E: Leslie.Chong@Imugene.com

Follow us on Twitter [@TeamImugene](https://twitter.com/TeamImugene)

Like us on Facebook [@Imugene](https://www.facebook.com/Imugene)

Connect with us on LinkedIn [@Imugene Limited](https://www.linkedin.com/company/Imugene-Limited)

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technology seeks to harness the body's immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates aimed at treating a variety of

cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become a foundation treatment for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.